Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
Saved in:
| Title: | Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. |
|---|---|
| Authors: | O'Connell CL; Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California., Baer MR; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Ørskov AD; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; The Danish Stem Cell Center (Danstem), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Saini SK; Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark., Duong VH; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Kropf P; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Hansen JW; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; The Danish Stem Cell Center (Danstem), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Tsao-Wei D; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California., Jang HS; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Emadi A; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Holmberg-Thyden S; Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark., Cowland J; Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark., Brinker BT; Medical Oncology, Cancer and Hematology Centers of West Michigan, Grand Rapids, Michigan., Horwood K; Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California., Burgos R; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Hostetter G; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Youngblood BA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee., Hadrup SR; Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark., Issa JP; Coriell Institute for Medical Research, Camden, New Jersey., Jones P; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Baylin SB; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Siddiqi I; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California., Grønbaek K; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; The Danish Stem Cell Center (Danstem), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Dec 15; Vol. 28 (24), pp. 5306-5316. |
| Publication Type: | Clinical Trial, Phase I; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
